Testosterone treatment of men with mild cognitive impairment and low testosterone levels
- PMID: 25392187
- PMCID: PMC10852633
- DOI: 10.1177/1533317514556874
Testosterone treatment of men with mild cognitive impairment and low testosterone levels
Abstract
Introduction: This study investigated the effects of testosterone (T) treatment on cognition, mood, and quality of life in men with mild cognitive impairment (MCI) and low serum T levels.
Methods: A total of 351 community-dwelling men were screened, and 37 men evidenced both MCI and low T of whom 27 agreed for further screening. Twenty-two met all the study inclusion/exclusion criteria and enrolled in a 6-month randomized, double-blind, placebo-controlled study.
Results: Total T levels significantly increased in the T treatment group. No significant changes were observed in measures of cognition, mood, or quality of life other than improvement in 1 objective measure of verbal memory (P < .05) and decreased depression symptoms (P < .02) in the treatment group.
Conclusions: Testosterone treatment may modestly improve verbal memory and depression symptoms in men with both MCI and low T.
Keywords: cognition; low serum testosterone; mild cognitive impairment; quality of life; testosterone treatment; verbal memory.
© The Author(s) 2014.
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men.Psychoneuroendocrinology. 2007 Jan;32(1):72-9. doi: 10.1016/j.psyneuen.2006.10.008. Epub 2006 Dec 4. Psychoneuroendocrinology. 2007. PMID: 17145137 Free PMC article. Clinical Trial.
-
Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.Arch Neurol. 2006 Feb;63(2):177-85. doi: 10.1001/archneur.63.2.nct50002. Epub 2005 Dec 12. Arch Neurol. 2006. PMID: 16344336 Clinical Trial.
-
Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment.Neurology. 2005 Jun 28;64(12):2063-8. doi: 10.1212/01.WNL.0000165995.98986.F1. Neurology. 2005. PMID: 15985573 Clinical Trial.
-
Effects of Testosterone Supplementation on Separate Cognitive Domains in Cognitively Healthy Older Men: A Meta-analysis of Current Randomized Clinical Trials.Am J Geriatr Psychiatry. 2019 Nov;27(11):1232-1246. doi: 10.1016/j.jagp.2019.05.008. Epub 2019 May 20. Am J Geriatr Psychiatry. 2019. PMID: 31296441 Review.
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
Cited by
-
Testosterone deficiency in men with end stage renal disease and kidney transplantation: a narrative review.Int J Impot Res. 2024 Apr 13. doi: 10.1038/s41443-024-00890-x. Online ahead of print. Int J Impot Res. 2024. PMID: 38615112 Review.
-
Sex steroid and cognitive function among community-dwelling older men with or without vascular risk factors: a cross-sectional study.BMC Geriatr. 2024 Feb 13;24(1):147. doi: 10.1186/s12877-024-04727-6. BMC Geriatr. 2024. PMID: 38350861 Free PMC article.
-
Effects of testosterone enanthate on aggression, risk-taking, competition, mood, and other cognitive domains during 28 days of severe energy deprivation.Psychopharmacology (Berl). 2024 Mar;241(3):461-478. doi: 10.1007/s00213-023-06502-8. Epub 2023 Dec 1. Psychopharmacology (Berl). 2024. PMID: 38038817 Free PMC article. Clinical Trial.
-
Sex-based differences in effector cells of the adaptive immune system during Alzheimer's disease and related dementias.Neurobiol Dis. 2023 Aug;184:106202. doi: 10.1016/j.nbd.2023.106202. Epub 2023 Jun 15. Neurobiol Dis. 2023. PMID: 37330146 Free PMC article. Review.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
References
-
- Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol. 2004;39 (11-12):1633–1639. - PubMed
-
- Moffat SD, Zonderman AB, Metter EJ, Smith AD. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62 (2):188–193. - PubMed
-
- Chu LW, Tam S, Lee PW, et al. . Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf). 2008;68 (4):589–598. - PubMed
-
- Chu LW, Tam S, Wong RL, et al. . Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men. J Alzheimers Dis. 2010;21 (4):1335–1345. - PubMed
-
- Morley JE, Kaiser F, Raum WJ, et al. . Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progessive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor to 1 growth hormone. Proc Natl Acad Sci U S A. 1997;94 (14):7537–7542. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous